Trisomy 8 in a patient who responded to therapy with all‐<i>trans</i>‐retinoic acid and developed paroxysmal nocturnal haemoglobinuria

Viniou, Nora‐Athina; Michali, Evi; Meletis, John; Andreopoulos, Anastasios; Vaiopoulos, George; Stavroyianni, Niki; Loukopoulos, D; Yataganas, Xenophon

doi:10.1046/j.1365-2141.1997.d01-2123.x

Cited by 10 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Apart from the patients suffering from de novo PNH, pathological links to other stem cell disorders like AA and MDS have often been described (Jin et al., 1996; Nishimura et al., 1996; Teramura & Mizoguchi, 1996; Viniou et al., 1997; Iwanaga et al., 1998; Azenishi et al., 1999; Schrezenmeier et al., 2000; Socie et al., 2000). For example, in a study investigating 40 patients with MDS, 10% of the patients showed an increased percentage of GPI‐deficient cells (Iwanaga et al., 1998).…”

Section: Discussionmentioning

confidence: 99%

A standardized flow cytometric method for screening paroxysmal nocturnal haemoglobinuria (PNH) measuring CD55 and CD59 expression on erythrocytes and granulocytes

Oelschlaegel

Besson²,

Arnoulet

et al. 2001

Clinical &Amp; Laboratory Haematology

View full text Add to dashboard Cite

PNH is a disorder of the pluripotent stem cells resulting in a deficient expression of membrane-bound GPI-anchored proteins in different cell types. Several flow cytometric approaches are designed to detect this antigen deficiency. But they all require drawing and testing of normal samples as control. Therefore, in the present study two flow cytometric assays for the detection of CD55 and CD59 deficiency in erythrocytes (REDQUANT CD55/CD59) and granulocytes (CELLQUANT CD55/CD59) are proposed. Precalibrated beads are used to define the cut off between normal and deficient cell populations. The specificity of the tests has been evaluated in healthy blood donors (n=52) resulting in a clear and reproducible cut off (3%) for the normal percentage of GPI-deficient cells. This cut off has been confirmed in leukaemia and lymphoma patients not suspected for developing PNH. The sensitivity has been tested in patients suffering from known PNH (n=23). Both tests performed in combination allowed a reliable detection of PNH in all patients showing antigen deficiencies in both cell types in most patients (20/23). In contrast, the PNH clones in the investigated patients with MDS (4/19) or AA (4/22) were present in granulocytes or erythrocytes, only. This underlines the necessity of analysing erythrocytes as well as granulocytes. Preliminary data regarding a possible correlation between disease activity and percentage of antigen-deficient cells lead to the assumption that haemolytic crises can only be determined on granulocytes whereas deficient erythrocytes disappeared due to complement-mediated lysis of the PNH clone. In conclusion, the combination of the test kits enables the differential diagnosis of PNH clones in a standardized, simple and rapid approach which may have therapeutic consequences.

show abstract

Section: Discussionmentioning

confidence: 99%

A standardized flow cytometric method for screening paroxysmal nocturnal haemoglobinuria (PNH) measuring CD55 and CD59 expression on erythrocytes and granulocytes

Oelschlaegel

Besson²,

Arnoulet

et al. 2001

Clinical &Amp; Laboratory Haematology

View full text Add to dashboard Cite

show abstract

“…Actualmente se están haciendo estudios con la eritropoyetina recombinante humana (16) (pues, se supone que sólo estimula los clones normales de hematíes) y el ácido transretinoico (de forma muy limitada, ya que sólo se ha obtenido aumento del nivel de hemoglobina en patología asociada a trisomía 8) (17).…”

Section: Monocitosunclassified

Hemoglobinuria paroxística nocturna: Novedades patogénicas y terapéuticas

Pérez

Benayas

Arranz

et al. 2001

An. Med. Interna (Madrid)

View full text Add to dashboard Cite

RESUMENLa hemoglobinuria paroxística nocturna (HPN) es la traducción clínica de una alteración de las células hematológicas, cuya etiopatogenia ha sido desconocida hasta hace relativamente poco tiempo. Intentamos resumir los aspectos más relevantes del proceso, y definir las características patogénicas, responsables de las manifestaciones clínicas de la enfermedad.PALABRAS CLAVE: HPN. Etiología. Patogenia. Pig-A. Proteínas de anclaje del glucosilfosfatidilinositol. ABSTRACTParoxysmal Nocturnal Haemoglobinuria (PNH) is a clinical manifestation of an haemathology cell disease, whose etiology has been unknown for many years. We try to resume the most relevant facts of this entity and to define the pathogenesis which is responsible of the clinical manifestations of the disease.

show abstract

Advances in the therapy of the myelodysplastic syndromes

Kouides

Bennett²

Diagnostic and Therapeutic Advances in Hematologic Malignancies

View full text Add to dashboard Cite

Trisomy 8 in a patient who responded to therapy with all‐trans‐retinoic acid and developed paroxysmal nocturnal haemoglobinuria

Cited by 10 publications

References 5 publications

A standardized flow cytometric method for screening paroxysmal nocturnal haemoglobinuria (PNH) measuring CD55 and CD59 expression on erythrocytes and granulocytes

A standardized flow cytometric method for screening paroxysmal nocturnal haemoglobinuria (PNH) measuring CD55 and CD59 expression on erythrocytes and granulocytes

Hemoglobinuria paroxística nocturna: Novedades patogénicas y terapéuticas

Advances in the therapy of the myelodysplastic syndromes

Contact Info

Product

Resources

About